此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma (SCOPE Plus)

2026年9月8日 更新者:Scancell Ltd

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Study of iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma

This Phase 3 clinical trial is evaluating whether adding iSCIB1+, an investigational DNA-based cancer vaccine, to standard immunotherapy with nivolumab and ipilimumab can improve outcomes for people with advanced unresectable melanoma.

Participants will be randomly assigned to receive either iSCIB1+ or a placebo, in addition to standard treatment with nivolumab and ipilimumab. Neither participants nor study doctors will know which treatment has been assigned. The study will compare how long participants live without their cancer worsening, overall survival, tumor response, safety, and quality of life.

iSCIB1+ is designed to stimulate the immune system to recognize and attack melanoma cells by targeting proteins commonly found on melanoma tumors. Earlier studies have shown encouraging signs of immune activation and anti-tumor activity when iSCIB1+ was combined with checkpoint inhibitor immunotherapy. This study aims to determine whether adding iSCIB1+ to standard immunotherapy provides additional benefit compared with standard immunotherapy alone

研究概览

详细说明

This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of iSCIB1+ in combination with nivolumab and ipilimumab as first-line treatment for adults with advanced unresectable Stage III or Stage IV melanoma who express specific human leukocyte antigen (HLA) types.

Checkpoint inhibitor therapy has significantly improved outcomes for patients with advanced melanoma; however, many patients still experience disease progression. iSCIB1+ is a DNA-based therapeutic cancer vaccine designed to enhance immune recognition of melanoma-associated antigens and may improve the depth and durability of anti-tumor responses when used alongside checkpoint inhibition.

Approximately 550 participants will be randomized in a 1:1 ratio to receive either:

iSCIB1+ plus nivolumab and ipilimumab, or Placebo plus nivolumab and ipilimumab.

The primary objective is to determine whether the addition of iSCIB1+ improves progression-free survival (PFS) compared with placebo when both are administered in combination with nivolumab and ipilimumab.

Secondary objectives include evaluation of:

Overall survival (OS) Objective response rate (ORR) Duration of response (DoR) Disease control rate (DCR) Safety and tolerability Patient-reported quality of life outcomes

The study will also explore immune and biomarker responses in selected participants to better understand the relationship between vaccine-induced immune responses and clinical outcomes.

Participants will continue to be followed for disease progression, survival, safety, and other outcomes for up to four years after randomization.

研究类型

介入性

注册 (估计的)

550

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Colorado
      • Aurora、Colorado、美国、80045
        • University of Colorado Cancer Center
        • 首席研究员:
          • Sapna Patel
      • London、英国
        • Mount Vernon Cancer Centre
        • 首席研究员:
          • Heather Shaw

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

5.1.Inclusion Criteria

  1. Participant has histologically confirmed, unresectable Stage III or Stage IV melanoma as defined by the AJCC (Gershenwald et al., 2017). Participants with a diagnosis of melanoma of unknown primary are eligible.
  2. Participant is positive for at least one of the following HLA alleles: HLA- with an HLA type of any one of HLA MHC class I: A2, A3, A31, Bw4, B44 and B35.
  3. Participant has been clinically evaluated, and checkpoint inhibition has been determined to be an appropriate treatment for their advanced disease.
  4. Participant's BRAF status must be known; participants with BRAF mutation positive disease may be enrolled without BRAF-inhibitor treatment at the discretion of the Study Investigator.
  5. Participant has at least one measurable lesion per RECIST 1.1 criteria by computed tomography CT scan or MRI.
  6. Participant is at least 18 years of age.
  7. Participant has a life expectancy of more than 6 months.
  8. Participant has an ECOG performance status of 0 or 1.
  9. Participant has adequate organ function as determined by the following laboratory values:

    Absolute neutrophil count ≥ 1.5 x 109/L Lymphocyte count ≥0.5 x 109/L Platelet count ≥100 x 109/L Hemoglobin >9 g/dL (> 5.6 mmol/L) Serum creatinine or creatinine clearance ≤1.5x ULN >50 mL/min Serum total bilirubin ≤1.5 x ULN or <3.0 mg/dL if participant has Gilbert's syndrome Serum transaminases, AST and ALT ≤2.5 x ULN or ≤5.0 x ULN if liver metastases present

  10. Participant must be able and willing to provide written IRB/REC-approved informed consent prior to any study-related procedure.
  11. Women of childbearing potential must agree to use highly effective contraceptive methods prior to study entry, for the whole duration of study treatment, and for at least 5 months following the last dose or in accordance with the SmPC of the IC SOC CPI (whichever is most conservative).

    See Appendix D: Guidance on Acceptable Contraceptive Methods for full guidance..

  12. Women of childbearing potential must have a negative serum pregnancy test at screening and within two days before IMP (or placebo) administration.
  13. Participant must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.

5.2.Exclusion Criteria

  1. Participant has a diagnosis of mucosal, ocular or acral melanoma.
  2. Participant has received prior systemic anti-PD1 treatment for advanced disease.
  3. Participant has received prior adjuvant treatment, defined as treatment following resection of all detectable disease, within 6 weeks of Day 1 (first dose of IMP).
  4. Participant has BRAF mutation positive disease with evidence of rapid PD.
  5. Participant has symptomatic brain metastases or carcinomatous meningitis. Symptomatic brain metastases are defined as brain metastases causing neurological signs or symptoms attributable to intracranial disease and/or requiring corticosteroid therapy for the management of brain metastasis-related symptoms. Participant is expected to require and elect any other form of systemic or localized anticancer therapy while receiving study treatment.
  6. Participants receive treatment with any investigational product within 28 days (or five half-lives of the treatment concerned if longer than 28 days) prior to Day 1.
  7. Participant has had a previous or current malignancy within 5 years, with the exception of melanoma and curatively treated local tumors.
  8. Participant has a concurrent illness/diagnosis which are uncontrolled and/or would preclude study conduct and assessment.
  9. Participant has NYHA class III or IV heart disease.
  10. Participant has a history of severe hypersensitivity reaction to treatment with a mAb.
  11. Participant has an active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents above physiological dosing.
  12. Received a live vaccine or non-live vaccine (including COVID-19 vaccines) within 7 days prior to first dose of study treatment.
  13. Participant has received systemic steroids or is receiving any other form of immune suppressant medication above physiological dosing within 7 days of Day 1.
  14. Participant is positive for HIV-1/2 infection or is positive for HBsAg or HCV antigen consistent with active infection.
  15. Participant has a known current or recent history (within the last year) of substance abuse including illicit drugs or alcohol to the extent where it would negatively affect compliance with the trial protocol based on Study Investigator's decision.
  16. Participant has received a solid organ transplant.
  17. Participant is breastfeeding during the study treatment phase, and for at least five months following the last dose or in accordance with the SmPC of I/N (whichever is most conservative).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:iSCIB1+ in combination with Ipilimumab and Nivolumab
Participants will receive iSCIB1+ in combination with standard immunotherapy consisting of nivolumab and ipilimumab. Treatment will be administered according to the protocol-defined dosing schedule. Following induction treatment with nivolumab and ipilimumab, participants will continue nivolumab maintenance therapy. This arm is designed to evaluate whether the addition of iSCIB1+ improves clinical outcomes compared with placebo when administered in combination with nivolumab and ipilimumab in participants with advanced unresectable melanoma.
iSCIB1+ is a DNA-based therapeutic cancer vaccine designed to enhance T-cell immune responses against melanoma-associated antigens. The vaccine encodes epitopes derived from glycoprotein 100 (gp100) and tyrosinase-related protein 2 (TRP-2) that are delivered using Scancell's ImmunoBody® platform. In this study, iSCIB1+ is administered by intramuscular injection with electroporation in combination with nivolumab and ipilimumab for the treatment of advanced unresectable melanoma. The intervention is intended to augment anti-tumor immune responses and improve clinical outcomes when added to standard checkpoint inhibitor therapy.
其他名称:
  • ImmunoBody®
Nivolumab is a programmed death-1 (PD-1) immune checkpoint inhibitor monoclonal antibody administered according to the protocol-defined treatment regimen. Ipilimumab is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) immune checkpoint inhibitor monoclonal antibody administered according to the protocol-defined treatment regimen.
其他名称:
  • BMS-936558
  • 欧狄沃
  • BMS-734016
  • 耶沃伊
安慰剂比较:Placebo + Nivolumab and Ipilimumab
Participants will receive placebo in combination with standard immunotherapy consisting of nivolumab and ipilimumab. Treatment will be administered according to the protocol-defined dosing schedule. Following induction treatment with nivolumab and ipilimumab, participants will continue nivolumab maintenance therapy. This arm serves as the comparator for evaluating the efficacy and safety of iSCIB1+ when added to standard first-line immunotherapy in participants with advanced unresectable melanoma.
Nivolumab is a programmed death-1 (PD-1) immune checkpoint inhibitor monoclonal antibody administered according to the protocol-defined treatment regimen. Ipilimumab is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) immune checkpoint inhibitor monoclonal antibody administered according to the protocol-defined treatment regimen.
其他名称:
  • BMS-936558
  • 欧狄沃
  • BMS-734016
  • 耶沃伊
The placebo is a Dulbecco's Phosphate-Buffered Saline (D-PBS) solution for intramuscular injection that contains no iSCIB1+ plasmid DNA. It is formulated to be visually and physically indistinguishable from iSCIB1+ and is administered using the same procedures to maintain study blinding. The placebo serves as the comparator in this trial when administered in combination with nivolumab and ipilimumab.
其他名称:
  • Dulbecco's Phosphate-Buffered Saline
  • D-PBS

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Progression-Free Survival (PFS)
大体时间:Up to 4 years after randomization.
Progression-free survival (PFS), defined as the time from randomization to the earliest occurrence of disease progression per RECIST v1.1 as assessed by Blinded Independent Central Review (BICR) or death from any cause.
Up to 4 years after randomization.

次要结果测量

结果测量
措施说明
大体时间
Overall Survival (OS)
大体时间:Up to approximately 4 years months after randomization.
Overall survival, defined as the time from randomization to death from any cause.
Up to approximately 4 years months after randomization.
Objective Response Rate (ORR)
大体时间:Up to 4 years after randomization.
Objective response rate, defined as the proportion of participants achieving a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by BICR.
Up to 4 years after randomization.
Duration of Response (DoR)
大体时间:Up to 4 years after randomization.
Duration of response, defined as the time from first documented objective response (CR or PR) until disease progression per RECIST v1.1 or death from any cause.
Up to 4 years after randomization.
Disease Control Rate (DCR)
大体时间:Up to 4 years after randomization.
Disease control rate, defined as the proportion of participants achieving complete response, partial response, or stable disease according to RECIST v1.1 as assessed by BICR.
Up to 4 years after randomization.
Incidence of Treatment-Emergent Adverse Events (TEAEs)
大体时间:From informed consent and up to 4 years from randomization
Incidence, nature, severity, and relationship of treatment-emergent adverse events, graded according to NCI CTCAE.
From informed consent and up to 4 years from randomization
Incidence of Serious Adverse Events (SAEs)
大体时间:From informed consent and up to 4 years from randomization
Incidence of serious adverse events.
From informed consent and up to 4 years from randomization
Change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score
大体时间:From informed consent and up to 4 years from randomization
The EORTC QLQ-C30 Global Health Status/Quality of Life scale ranges from 0 to 100, with higher scores indicating better quality of life.
From informed consent and up to 4 years from randomization
Change from baseline in EQ-5D-5L Health Utility Index Score
大体时间:From informed consent and up to 4 years from randomization
EQ-5D-5L index values are derived from participant responses across five health dimensions.
From informed consent and up to 4 years from randomization
Number of participants reporting symptomatic adverse events according to PRO-CTCAE items
大体时间:From informed consent and up to 4 years from randomization
Participant-reported symptom burden will be assessed using selected PRO-CTCAE symptom items. Individual responses are scored according to the PRO-CTCAE scoring manual.
From informed consent and up to 4 years from randomization

其他结果措施

结果测量
措施说明
大体时间
Immune Response to iSCIB1+: Change from baseline in antigen-specific T-cell response measured by IFN-γ ELISpot assay
大体时间:From informed consent and up to 4 years from randomization
Antigen-specific cellular immune responses to TRP-2 and gp100 melanoma antigens will be evaluated using IFN-γ ELISpot assays on peripheral blood samples collected from a subset of participants.
From informed consent and up to 4 years from randomization
Change from baseline in exploratory tumor, blood, and immune biomarker levels
大体时间:From informed consent until completion of study participation (i.e. up to 4 years)
Analysis of changes in exploratory tumor, blood, and immune biomarkers measured in tissue and blood samples collected during the study. Biomarker measurements may include gene expression, circulating tumor DNA, immune cell populations, cytokines, and other exploratory markers.
From informed consent until completion of study participation (i.e. up to 4 years)
Change from baseline in exploratory immune-related biomarker measurements
大体时间:From baseline and up to 4 years from day 1.
Exploratory assessment of changes in immune-related biomarkers, including PD-1, PD-L1, CTLA-4, CD3+, CD4+, CD8+ cell markers, cytokines, T-cell receptor repertoire, tumor infiltrating lymphocytes, and circulating tumor DNA measured in tumor tissue and blood samples.
From baseline and up to 4 years from day 1.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2028年12月1日

研究完成 (估计的)

2032年12月1日

研究注册日期

首次提交

2026年9月3日

首先提交符合 QC 标准的

2026年9月8日

首次发布 (实际的)

2026年9月11日

研究记录更新

最后更新发布 (实际的)

2026年9月11日

上次提交的符合 QC 标准的更新

2026年9月8日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅